Prostate Cancer
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: SOLAR & SATURN Clinical Trials - Comparing the Progression of De Novo vs. Recurrent PSMA-Defined Oligo-M1 Prostate Cancer Following Systemic Therapy & Tumor-Directed Therapy
FEATURING
Amar Kishan
- 6 views
- April 12, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: TRITON3 Final OS and Safety - Rucaparib vs. Docetaxel or Second-Generation ARPI in mCRPC
FEATURING
Alan Bryce
- 2 views
- April 11, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Initial Biopsy Results Screening for Inherited Risk of Developing Aggressive Prostate Cancer - PATROL Study
FEATURING
Daniel Lee
- 6 views
- April 9, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Choice of Androgen Receptor Pathway Inhibitors (ARPi) by Disease Volume and Timing of Metastases in mHSPC
FEATURING
Syed Arsalan Ahmed Naqvi
- 14 views
- April 9, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Can MRI Accurately Replace Confirmatory Biopsy for Prostate Cancer Patients on Active Surveillance?
FEATURING
Matthew Cooperberg
- 27 views
- April 2, 2025
- 1
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Age-Related Outcomes of Darolutamide + ADT and Docetaxel in mHSPC: Subgroup Analysis From ARASENS
FEATURING
Joan Carles
- 17 views
- March 27, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: HSD3B1 and OS in Metastatic and Non-Metastatic Prostate Cancer Starting ADT With ENZ or AAP - STAMPEDE Trial
FEATURING
Nima Sharifi
- 13 views
- March 12, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Impact of BRCA Status in mCRPC Patients Undergoing Abiraterone +/- SBRT - ARTO Trial
FEATURING
Giulio Francolini
- 3 views
- March 11, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Adrenal Androgens and OS in Men With mCRPC Treated With ENZ or ENZ/AAP - Alliance Trial
FEATURING
Nima Sharifi
- 13 views
- March 7, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Neoadjuvant Intra-Arterial 177Lu-PSMA-617 in High-Risk Localized or Locally Advanced Prostate Cancer - LUPUS Trial
FEATURING
Claudia Kesch
- 10 views
- March 7, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Efficacy of 177Lu-PSMA-617 +/- ARPIs for the Treatment of mCRPC - VISION Secondary Analysis
FEATURING
Omid Yazdanpanah
- 105 views
- March 6, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: AI-Derived Tumor Volume From Baseline MRI and Postprostatectomy Outcomes Following Neoadjuvant Hormonal Therapy for High-Risk Prostate Cancer
FEATURING
David Yang
- 7 views
- March 6, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Summary: Advances in Metastatic Prostate Cancer Treatment - AI, Genomics, Radioligand Therapy, and Drug Comparisons
FEATURING
Pedro Barata
- 131 views
- March 4, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: mCRPC Survival Outcomes With 177Lu-PSMA-617 Based on Line of Therapy
FEATURING
Nicolas Sayegh
- 131 views
- February 25, 2025
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: The Influence of Boosting Gut Health and Phytochemical-Rich Foods in Men With Prostate Cancer
FEATURING
Robert Thomas
- 231 views
- February 19, 2025
- 6
Insights from 2025 ASCO® GU Annual Meeting
ASCO® GU 2025 Insights: Final Outcomes of the ARNEO Trial - Neoadjuvant Degarelix +/- Apalutamide Before Radical Prostatectomy in High-Risk Prostate Cancer
FEATURING
Alexander Giesen
- 36 views
- February 18, 2025